Drug Profile

LEAD 472

Alternative Names: LEAD-472

Latest Information Update: 16 Sep 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator LeadArtis
Class Antineoplastics; Immunotherapies; Recombinant fusion proteins; Single-domain antibodies
Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants; Tumour necrosis factor receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Research Breast cancer; Lung cancer; Ovarian cancer; Pancreatic cancer; Testicular cancer; Thyroid cancer

16 Sep 2022 LEAD 472 is available for licensing as of 16 Sep 2022. https://leadartis.com/contact-us/
16 Sep 2022 LeadArtis has patent protections in the EU, prior to September 2022 (LeadArtis pipeline, September 2022)
16 Sep 2022 LeadArtis has pending patent applications in the EU, prior to September 2022 (LeadArtis pipeline, September 2022)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com